Martin Shkreli livestreamed violation of pharma ban, FTC says
The FTC states that Martin Shkreli livestreamed himself discussing biotech stock investments, directly violating his lifetime ban from the pharmaceutical industry.
Stock photo for illustration only, not from the actual event
- Martin Shkreli claimed in a livestream that he still trades biotech stocks.
- The action directly violates his lifetime ban from the pharmaceutical industry.
- The Federal Trade Commission (FTC) is monitoring the reported violation.
Martin Shkreli, the controversial former pharmaceutical executive, has once again drawn regulatory scrutiny after allegedly broadcasting himself engaging in activities prohibited by a federal court order and regulatory settlement that barred him from the drug industry for life.
According to reports from Ars Technica, Shkreli made statements during an online livestream indicating that he continues to monitor and participate in the biotech market, despite the strict legal prohibitions against him.
Stock photo for illustration only, not from the actual event
During the broadcast, Shkreli explicitly remarked, "I can always find a couple of biotech stocks to smoke," highlighting his ongoing involvement in the sector that he was legally mandated to avoid.
A lifetime ban from an entire industry is an exceptionally severe regulatory penalty reserved for egregious corporate misconduct. When an individual bound by such a strict order publicly flaunts potential continued involvement on a livestream, it immediately triggers red flags for regulatory bodies like the FTC, potentially leading to contempt of court charges or further legal penalties.
The Federal Trade Commission (FTC) is reportedly reviewing the details of the broadcast to determine the extent of the violation and whether formal enforcement actions or legal consequences will follow.
Source: Ars Technica
Found something wrong in this article? Report an issue with this article
Comments
Leave a Comment